DOAC Dos and Don’ts

Cardiology and hematology experts from Mayo Clinic review how and when DOACs should be deployed in patients with nonvalvular atrial fibrillation or at risk for VTE. They also address approved and pipeline reversal agents.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s